Boston Scientific Corporation (NYSE:BSX) Relative Strength Index (RSI) is 62.79, with weekly volatility at 2.35% and ATR at 0.93. The BSX stock’s 52-week price range has touched low of $24.10 and a $43.16 high. Intraday shares traded counted 10.9 million, which was 11.16% higher than its 30-day average trading volume of 12.27M. Its shares traded higher over the last trading session, gaining 3.08% on 02/22/21. The shares fell to a low of $37.85 before closing at $39.20. BSX’s previous close was $38.03 while the outstanding shares total 1.43B. The firm has a beta of 0.87.
Investors have identified the Medical Devices company Boston Scientific Corporation as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $55.38 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Boston Scientific Corporation (BSX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For BSX, the company has in raw cash 2.02 billion on their books with 11.0 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 6.16 billion total, with 3.3 billion as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 1.79 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BSX sounds very interesting.
Is the stock of BSX attractive?
In related news, EVP Pres MedSurg, Pierce David A sold 1,540 shares of the company’s stock in a transaction that recorded on Feb 16. The sale was performed at an average price of 38.28, for a total value of 58,951. As the sale deal closes, the EVP & Pres, Eur, Mid-East, Afr, Thepaut Eric Francis Yves now sold 28,883 shares of the company’s stock, valued at 1,116,354. Also, EVP&Pres, Periph Intervent, Mirviss Jeffrey B. sold 5,494 shares of the company’s stock in a deal that was recorded on Feb 12. The shares were price at an average price of 38.75 per share, with a total market value of 212,893. Following this completion of acquisition, the EVP&Pres, Asia Pacific, Butcher Arthur C now holds 16,902 shares of the company’s stock, valued at 665,812. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.20%.
21 out of 27 analysts covering the stock have rated it a Buy, while 5 have maintained a Hold recommendation on Boston Scientific Corporation. 0 analysts has assigned a Sell rating on the BSX stock. The 12-month mean consensus price target for the company’s shares has been set at $43.36.